A reference for TB-500 (thymosin beta-4 fragment) research: mechanism, what the animal and human evidence actually covers, safety findings, legal status, and how to verify a vial. Research use only; we do not publish dosing protocols.
Evidence quality analysis across 6 applications — tendon repair, cardiac protection, wound healing, and neuroregeneration.
Full molecular profile: amino acid sequence, mechanism of action, key signaling pathways, and research highlights.
Why the two are discussed together: how their mechanisms differ, and how thin the evidence for combining them is.
Mechanism, what the published animal studies used (with citations), and which certificate tests matter for this compound.
Concentration per mL for a given vial size and diluent volume, for preparing laboratory solutions.
How long a lyophilized vial keeps at room temperature, and why an opened solution does not.
Common questions about TB-500 from researchers
TB-500 is a synthetic peptide derived from Thymosin Beta-4, a naturally occurring protein found in virtually all human and animal cells. It is primarily studied for its role in tissue repair, wound healing, and angiogenesis. TB-500 acts by sequestering G-actin, which promotes cell migration and the formation of new blood vessels.
In animal and cell models, TB-500 and thymosin beta-4 are studied for tendon and ligament repair, cardiac tissue after injury, wound healing, neuroregeneration and inflammation. Human data exist only for full-length thymosin beta-4, developed by RegeneRx Biopharmaceuticals; its most advanced program is an eye-drop formulation, and an injectable cardiac program has not produced published efficacy results. None of this establishes an effect for the TB-500 fragment in people.
TB-500 and BPC-157 are both studied for tissue repair but work through distinct mechanisms. TB-500 primarily acts through actin sequestration and angiogenesis, while BPC-157 works through VEGF upregulation and nitric oxide pathways. They are often stacked together because their mechanisms are complementary rather than redundant.
No. TB-500 is not an approved drug, the fragment has never been tested in a human clinical trial, and the amounts used in published animal studies were chosen for those models and routes; they do not translate into a human figure. The 'loading and maintenance' schedules that circulate online come from forums, not trials. Compound Review does not publish dosing protocols. TB-500 is sold for laboratory research only and is not for human or animal consumption; the research profile lists the published studies with citations for anyone reviewing the literature.
Strictly, TB-500 is a synthetic fragment of thymosin beta-4: the actin-binding region (residues 17–23, Ac-LKKTETQ) of the 43-residue protein. In practice vendors use the name for both the fragment and the full-length protein, which differ about fivefold in mass. Whether the fragment reproduces the full protein's studied effects has not been established. The measured mass on a certificate is the quickest way to see which one a vial contains.
≥99% purity · Third-party COA on every batch · Ships same day
Evidence analysis of TB-500 (Thymosin Beta-4): actin-sequestering mechanism, wound healing, and anti-inflammatory research.
Head-to-head comparison of BPC-157 and TB-500: mechanisms, healing applications, dosage, and which to choose.
BPC-157 and TB-500 stacking: synergistic mechanisms, combined dosage protocols, and research evidence.